Core Viewpoint - Recent announcements from China Europe Fund indicate a trend of limiting large purchases for several high-performing funds, including the China Europe Medical Innovation Fund managed by Ge Lan, which has a daily purchase limit of 100,000 yuan per account [1][3][14]. Fund Purchase Restrictions - Starting from August 11, 2025, the China Europe Medical Innovation Fund will suspend large purchases, conversions, and regular investment plans, with a limit of 100,000 yuan per account [3][5]. - This follows a similar restriction placed on another fund managed by Ge Lan, the China Europe Medical Health Fund, which has maintained a 100,000 yuan limit since January 2021 [1][3]. Fund Performance and Holdings - As of mid-2023, the China Europe Medical Innovation Fund has a total net asset value exceeding 8.2 billion yuan, with significant investments in the healthcare sector, accounting for 46.41% of its portfolio [6][7]. - The top ten holdings of the fund include notable companies such as 3SBio, with a year-to-date increase of nearly 400%, and all top ten stocks have shown an average increase of over 100% this year [6][8][9]. Market Trends and Fund Management - The recent surge in the innovative drug sector has led to a continuous rise in the unit net value of the China Europe Medical Innovation Fund, which recently surpassed 1.7 yuan, compared to a low of 0.9 yuan a year ago [9]. - The trend of limiting purchases is seen across the industry, with approximately 50 actively managed equity funds announcing similar restrictions since July, reflecting a cautious approach by fund managers to maintain investment strategy effectiveness and protect existing investors [14][15].

Core Viewpoint - Recent announcements from multiple high-performing funds under China Europe Fund indicate a trend of limiting large purchases to ensure stable fund operations and protect the interests of existing fund holders [1][3][15]. Fund Purchase Limitations - On August 9, China Europe Fund announced that starting from August 11, the China Europe Medical Innovation Fund would limit single-day purchases to 100,000 yuan per account [3][5]. - This is not the first instance; a similar limit was imposed on another medical fund managed by the same manager, Guo Lan, since January 2021 [1][2]. Fund Performance and Holdings - As of mid-2023, the China Europe Medical Innovation Fund had a total net asset value exceeding 8.2 billion yuan, with major investments in healthcare and manufacturing sectors, accounting for 46.41% and 41.99% of the portfolio, respectively [6][7]. - The top ten holdings of the fund include notable companies such as Sanofi Pharmaceutical and WuXi AppTec, with significant year-to-date price increases, including a nearly 400% rise for the largest holding, Sanofi Pharmaceutical [6][8]. Market Trends and Reactions - The recent surge in the innovative drug sector has led to substantial gains for the fund's holdings, with an average increase of over 100% for the top ten stocks this year [7][8]. - The fund's unit net value has also risen significantly, reaching 1.6874 yuan, compared to a low of below 0.9 yuan a year ago [9]. Broader Industry Context - The trend of limiting fund purchases is not isolated; approximately 50 actively managed equity funds have announced similar restrictions since July, reflecting a broader industry response to rapid inflows and the need to maintain investment strategy effectiveness [14][15]. - Industry experts suggest that these measures are aimed at controlling fund size to enhance investment efficiency and protect existing investors from potential losses due to market volatility [15][16].

8月9日，中欧基金发布公告称，基金经理葛兰管理的中欧医疗创新股票型证券投资基金（简称"中欧医 疗创新"），单日单账户限购10万元；基金经理邵洁管理的中欧科创主题混合型证券投资基金（简称"中 欧科创主题"），单日单账户限购100万元。 据不完全统计，7月以来，已有约50只主动权益基金发布限购公告，其中不乏最近一年涨幅居前的绩优 产品。 业内人士表示，从中长期维度来看，A股中枢有望震荡抬升。随着国内后续潜在催化因素增多，市场风 险偏好或持续回升。 知名基金经理旗下产品限购 一位公募人士向中国证券报记者表示，在公募行业高质量发展的要求下，基金公司在行情较好阶段主动 限购，科学控制规模，一定程度上能保证投资策略的有效性，让基金运作更加稳定，有助于切实保护持 有人利益。 三季度市场或维持向上趋势 业内人士表示，从中长期维度来看，A股中枢有望震荡抬升。随着国内后续潜在催化因素增多，市场风 险偏好或持续回升，预计后续A股将呈现更为明显的结构性特征。 中欧基金8月9日公告显示，为进一步保证基金稳定运作，保护基金份额持有人利益，由基金经理葛兰管 理的中欧医疗创新单日单账户限购10万元。Choice数据显示，截至8月8日，中欧医 ...

Group 1 - The core viewpoint of the articles is that several funds managed by China Universal Asset Management have announced purchase limits to ensure stable operations and protect the interests of fund holders [1][2][9] - China Universal Medical Innovation Fund, managed by Guo Lan, will limit single account purchases to 100,000 yuan starting August 11 [3][4] - The China Universal Science and Technology Theme Fund, managed by Shao Jie, will also impose a limit on large purchases over 1 million yuan from August 11 [6][7] Group 2 - As of the end of Q2, the China Universal Medical Innovation Fund had a scale of 8.114 billion yuan, reflecting a nearly 20% increase year-on-year, with a one-year return of 80.12%, ranking in the top 2 of its category [4][5] - The fund manager, Guo Lan, maintains a positive outlook on the innovative drug sector, citing increasing global competitiveness of domestic companies and supportive domestic policies [5] - The China Universal Science and Technology Theme Fund has a one-year return of 84.33%, also ranking in the top 2 of its category, benefiting from the explosive growth in the technology sector [7][8] Group 3 - The recent trend of fund purchase limits is seen across the industry, with approximately 50 actively managed equity funds announcing similar restrictions since July [10][11] - The rationale behind these limits is to control fund size, maintain investment strategy effectiveness, and protect existing investors from potential losses due to market volatility [10][11] - Fund managers are increasingly focusing on stable growth and the long-term profitability of their products rather than short-term performance spikes [11]

Core Viewpoint - Multiple high-performing funds managed by China Europe Fund have announced purchase limits to ensure stable fund operations and protect the interests of fund shareholders [2][3][10]. Fund Purchase Limits - On August 9, China Europe Fund announced that the China Europe Medical Innovation Fund would limit single-day purchases to 100,000 yuan starting August 11 [4][5]. - The China Europe Digital Economy Fund had already suspended large purchases over 1 million yuan starting August 6 [2][5]. - The China Europe Science and Technology Innovation Fund, managed by Shao Jie, will also suspend large purchases over 1 million yuan from August 11 [7]. Fund Performance - As of the end of Q2, the China Europe Medical Innovation Fund had a scale of 8.114 billion yuan, a nearly 20% increase year-on-year [5]. - The fund achieved a one-year return of 80.12%, ranking in the top 2% of its category as of August 8 [5]. - The China Europe Science and Technology Innovation Fund had a one-year return of 84.33%, also ranking in the top 2% of its category [7]. Market Context - The trend of fund purchase limits has been observed across approximately 50 actively managed equity funds since July, particularly among high-performing products [10][11]. - Industry insiders indicate that the recent wave of purchase limits is aimed at controlling fund size to maintain the effectiveness of investment strategies and protect existing shareholders from potential losses due to market volatility [11].

【导读】中欧数字经济混合暂停大额申购 8月6日，中欧数字经济混合基金宣布，即日起暂停100万元以上的大额申购。 | 基金名称 | 中欧数字经济混合型发起式证券投资基金 | | | --- | --- | --- | | 基金简称 | 中欧数字经济混合发起 | | | 基金主代码 | 018993 | | | 基金管理人名称 | 中欧基金管理有限公司 | | | 公告依据 | 《公开募集证券投资基金信息披露管理办法》、《中 欧数字经济混合型发起式证券投资基金基金合同》和 | | | | 《中欧数字经济混合型发起式证券投资基金招募说明 | | | | 书》的相关规定。 | | | 暂停相关业务的起始 | 暂停大额申购起始日 暂停大额定期定额投资起 | 2025年8月6日 | | | 暂停大额转换转入起始日 | 2025年8月6日 | | | | 2025年8月6日 | | | 始日 | | | | 限制申购金额(单位:元) | 1. 000. 000 | | | 限制转换转入金额(单位: | 1. 000. 000 | | 日、金额及原因说明 | 元) | | | | 限制定期定额投资金额 | 1. 000. 0 ...

8月6日，中欧基金发布公告称，为保证基金的稳定运作，保护基金份额持有人利益，公司决定自8月6日 （含）起，限制中欧数字经济混合发起的申购、转换转入及定期定额投资业务的金额，单日单个基金账 户对该基金任一类别基金份额的单笔或多笔累计申购、转换转入及定期定额投资业务的金额超过100万 元（不含），公司有权拒绝。数据显示，该基金由基金经理冯炉丹管理，截至8月5日，该基金近一年的 收益率超150%。 有业内人士指出，不少主动管理型基金选择限购，主要是为控制产品规模，避免短期内过快扩张。限购 有利于化解基金"船大难掉头"问题，还能限制部分资金借道基金买入停牌个股的套利行为，从而保护原 有基金份额持有人的利益。 展望后续行情，安联基金研究部总经理程彧认为，短期震荡不会改变市场向上的趋势。我国股票已进入 新一轮价值重估周期，背后驱动因素将在未来数年持续发挥作用。此外，维持优质科技资产在三季度或 有显著超额收益的判断。 8月1日，广发基金发布公告称，广发成长领航一年持有混合于8月4日起暂停5万元以上的大额申购。截 至8月5日，该基金近一年的回报率超147%。 除了上述主动权益基金以外，诺安多策略混合、中信保诚多策略混合（LO ...